Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1 diabetes mellitus

Abstract

For young children with T1DM, CSII therapy is comparable to MDI therapy with regard to glucose control but is associated with higher treatment satisfaction and improved quality of life.